Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

Home

/

RVTY

R

Revvity, Inc. (RVTY)

NYQ – Цена в реальном времени. Валюта: USD

115.94

+0.21 (0.18%)

Рынок открыт: Aug 12, 2026, 2:04 PM EDT

115.73

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Revvity to Present at Upcoming Investor Conferences

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 2026 Global Healthcare Conference Tuesday, September.

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.

Revvity Q2 Earnings Call Highlights

Revvity Q2 Earnings Call Highlights

Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker Revvity raised its annual profit and revenue forecasts on ‌Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-development tools and diagnostic testing products.

Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregnancies and is increasing globally due to rising maternal age and conditions such as diabetes an.

Revvity Announces Financial Results for the Second Quarter of 2026

Revvity Announces Financial Results for the Second Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related.

Revvity Board Declares Quarterly Dividend

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.